By Matthew Tuttle,

Tuttle Capital Management, LLC 

I think the AI biotech theme is going to be huge, and we’ve hit it a bunch in the newsletter. We talked about one issue that we haven’t hit though, it’s longevity. Andy talked about the possibility of soon being able to double life expectancy potentially. If this is true it could be a game changer for a number of different companies and industries. The exact kind of investment opportunities we look for.

• Therapeutics aimed at aging pathways: CRISPR/programmable medicine (CRSP, NTLA, EDIT), senotherapeutics and related biology (UBX—small/risky; watch for new senolytic entrants), telomerase & cell‐replicative programs (GERN), mitochondrial/metabolic modulation (CDXC), gene therapy platforms (RGNX).

• Obesity/metabolic disease leaders that extend healthspan: LLY, NVO.

• Early detection & screening that shift mortality curves: GH, EXAS, NTRA; sequencing/toolmakers that enable them: ILMN, DHR, TMO.

• Regenerative/repair and cardio devices that push healthy years higher: EW, MDT, RMD, INSP, AXGN, MESO (speculative).

• Plasma/biologic inputs with aging applications: GRFS (Alkahest).

• Infrastructure for chronic monitoring and prevention: ABT, DXCM; big-platform software/AI in R&D and real-world evidence: RXRX, SDGR.

• Insurers selling life insurance (not lifetime income): later mortality improves life claims experience; reinsurers with life books benefit first.

• Education, travel, premium senior housing, and fitness—if healthspan rises, consumption shifts toward “decades two and three of adulthood.”

• Annuity writers and defined-benefit pension sponsors: longevity risk extends payout tails; without re-pricing, earnings and funded status deteriorate.

• Governments with unfunded old-age promises: Social Security/Medicare math worsens unless eligibility ages, payroll taxes, or cost curves change.

• Providers geared to late-stage acute care rather than prevention and repair; long-term-care insurers if added years are not healthy years.

• Employers with static retirement assumptions: labor, benefit and upskilling budgets rise if careers run 50+ years.

Portfolio implications

• Tilt toward healthspan cash flows: metabolic disease franchises, screening/diagnostics, repair devices, and enabling tools. Use pure “longevity biotech” (senolytics, reprogramming) as a high-beta sleeve, position-sized.

• Own life insurers/reinsurers selectively; underweight annuity-heavy writers without credible hedging of longevity risk.

• Favor asset managers and wealth platforms exposed to longer contribution horizons and multi-decade glide paths.

• Expect multiples to expand for prevention/monitoring names as payers re-price toward “keep people well” economics.

• Hedge public-finance risk with selective muni exposure (shorter duration, higher coverage) and consider TIPS if longer lifespans reignite medical-cost inflation.

Retirement planning—what changes now

• Retirement age and savings rates move up: plan for 30–40-year drawdowns, not 20–25.

• Glide paths stay growth-tilted longer: more equities/higher real-asset mix deeper into one’s 60s–70s; later, ladder annuities only if priced for new longevity tables.

• Human capital becomes a core asset: mid-career re-training budgets and “second-act” earnings streams are no longer optional.

• Sequence-of-returns risk lasts longer: build cash/T-bill sleeves and dynamic withdrawal rules; consider deferred longevity insurance only from writers with robust reinsurance.

Fast watch list (public, liquid, investable)

• Healthspan core: LLY, NVO, GH, EXAS, NTRA, EW, RMD, INSP, ABT, DXCM.

• Platforms/enablers: ILMN, DHR, TMO, RXRX, SDGR.

• Speculative longevity biotech: CRSP, NTLA, EDIT, UBX, GERN, RGNX.

• Insurance tilt: MFC, PRU, MET (life); avoid/underweight annuity-heavy names without disclosed longevity hedges.

Bottom line Longevity isn’t a niche—it’s a cash-flow shock. Own the businesses that turn added healthy years into recurring revenue, and avoid liability structures that weren’t priced for a world where 95 is the new 70.

Catch a Longevity podcast with Andy Lee of Vincere Biosciences: https://www.youtube.com/watch?v=v6B_zmSfsSE&t=882s

The post WHO WINS IF AGING IS DEAD? appeared first on Sick Economics.